Premium
Treatment of refractory T‐cell malignancies using gemcitabine
Author(s) -
Sallah Sabah,
Wan Jim Y.,
Nguyen Nam P.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02743.x
Subject(s) - gemcitabine , refractory (planetary science) , medicine , toxicity , chemotherapy , salvage therapy , oncology , gastroenterology , confidence interval , biology , astrobiology
We have treated 10 patients with relapsed or refractory T‐cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m 2 on d 1, 8 and 15 of each 28‐d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20–35%). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T‐cell haematological neoplasms.